BR112018007686A2 - uso terapêutico de uma solução oftál¬mica aquosa es-teril - Google Patents

uso terapêutico de uma solução oftál¬mica aquosa es-teril

Info

Publication number
BR112018007686A2
BR112018007686A2 BR112018007686A BR112018007686A BR112018007686A2 BR 112018007686 A2 BR112018007686 A2 BR 112018007686A2 BR 112018007686 A BR112018007686 A BR 112018007686A BR 112018007686 A BR112018007686 A BR 112018007686A BR 112018007686 A2 BR112018007686 A2 BR 112018007686A2
Authority
BR
Brazil
Prior art keywords
sterile aqueous
aqueous ophthalmic
ophthalmic solution
therapeutic use
acetylcysteinyl
Prior art date
Application number
BR112018007686A
Other languages
English (en)
Inventor
Prinz Martin
Original Assignee
Croma Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croma Pharma Ges M B H filed Critical Croma Pharma Ges M B H
Publication of BR112018007686A2 publication Critical patent/BR112018007686A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a uma solução oftálmica aquosa estéril que compreende n-(n-acetilcisteinil-) quitosana ou um sal farmaceuticamente aceitável da mesma em uma solução de veiculo, em que a n-(n-acetilcisteinil-) quitosana tem um conteúdo de grupos de tiol livre em uma quantidade a partir de 80 µmol/g de polímero até 280 µmol/g de polímero, pra uso no tratamento de lesões na córnea.
BR112018007686A 2015-10-30 2016-10-27 uso terapêutico de uma solução oftál¬mica aquosa es-teril BR112018007686A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15192362 2015-10-30
PCT/EP2016/075939 WO2017072236A1 (en) 2015-10-30 2016-10-27 Therapeutic use of a sterile aqueous ophthalmic solution

Publications (1)

Publication Number Publication Date
BR112018007686A2 true BR112018007686A2 (pt) 2018-11-06

Family

ID=54476731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007686A BR112018007686A2 (pt) 2015-10-30 2016-10-27 uso terapêutico de uma solução oftál¬mica aquosa es-teril

Country Status (15)

Country Link
US (1) US10583152B2 (pt)
EP (1) EP3368007B1 (pt)
JP (1) JP6817300B2 (pt)
KR (1) KR20180066104A (pt)
CN (1) CN108348455B (pt)
AR (1) AR106494A1 (pt)
BR (1) BR112018007686A2 (pt)
CA (1) CA3001634C (pt)
ES (1) ES2796361T3 (pt)
IL (1) IL258785B (pt)
MX (1) MX2018004779A (pt)
PL (1) PL3368007T3 (pt)
PT (1) PT3368007T (pt)
RU (1) RU2741912C2 (pt)
WO (1) WO2017072236A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018202783A1 (en) 2017-05-03 2018-11-08 Croma-Pharma Gmbh Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders
CN113318075B (zh) * 2021-06-24 2022-09-13 四川普锐特药业有限公司 一种乙酰半胱氨酸溶液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
FR2692582B1 (fr) 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
AT406054B (de) 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
GB2386900B (en) 2002-03-25 2006-11-01 Johnson & Johnson Medical Ltd Use in wound dressings of chemically modified polysaccharides
PT2107913E (pt) 2006-12-22 2012-05-10 Croma Pharma Ges M B H Uso de polissacarídeos tiolados para aumento de tecidos
BRPI0807065A2 (pt) 2007-01-31 2017-03-21 Allergan Inc biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos
US9452592B2 (en) 2007-08-28 2016-09-27 Cryovac, Inc. Multilayer film having an active oxygen barrier layer with radiation enhanced active barrier properties
CA2698189C (en) 2007-08-31 2016-07-19 Benjamin J. Sun Three-dimensional printing methods and materials for making dental products
US9433636B2 (en) 2008-04-24 2016-09-06 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
US8530632B2 (en) 2008-04-24 2013-09-10 Medtronic Xomed, Inc. Chitosan-containing protective composition
AU2009240511B2 (en) 2008-04-24 2015-01-22 Medtronic, Inc. Thiolated chitosan gel
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US9439925B2 (en) * 2010-04-06 2016-09-13 Synedgen, Inc. Methods and compositions for treating wounds utilizing chitosan compounds
ITMI20120847A1 (it) * 2012-05-16 2013-11-17 Labomar S R L Formulazione per sostanze a bassa biodisponibilità.
AU2015257874B2 (en) 2014-05-07 2019-11-28 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome

Also Published As

Publication number Publication date
EP3368007B1 (en) 2020-03-18
CA3001634A1 (en) 2017-05-04
PT3368007T (pt) 2020-06-17
WO2017072236A1 (en) 2017-05-04
RU2018119126A3 (pt) 2020-02-14
MX2018004779A (es) 2018-06-19
RU2018119126A (ru) 2019-12-03
CN108348455B (zh) 2021-04-09
CA3001634C (en) 2023-05-23
CN108348455A (zh) 2018-07-31
IL258785B (en) 2022-08-01
AR106494A1 (es) 2018-01-17
IL258785A (en) 2018-06-28
JP6817300B2 (ja) 2021-01-20
RU2741912C2 (ru) 2021-01-29
US20180303865A1 (en) 2018-10-25
ES2796361T3 (es) 2020-11-26
JP2018535962A (ja) 2018-12-06
KR20180066104A (ko) 2018-06-18
EP3368007A1 (en) 2018-09-05
US10583152B2 (en) 2020-03-10
PL3368007T3 (pl) 2020-11-02

Similar Documents

Publication Publication Date Title
BR112016024454A2 (pt) solução oftálmica aquosa e método para o tratamento da síndrome do olho seco
MY197845A (en) Pharmaceutical composition
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112014026493A2 (pt) derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
MY171920A (en) Prevention and treatment of ocular conditions
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
BR112018069601A2 (pt) derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112015022161A2 (pt) implante intraocular contendo prostamida
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
BR112019000356A2 (pt) compostos e métodos para modulação de smn2
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
BR112014027582A8 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
BR112014019399A2 (pt) métodos de tratamento da fibrose
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
BR112018010052A2 (pt) peptídeos com propriedades antiangiogênicas, antilinfangiogênicas e antiedêmicas e formulações de nanopartícula
BR112018007686A2 (pt) uso terapêutico de uma solução oftál¬mica aquosa es-teril
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]